Menu

The latest from Magnitude Biosciences

A fully-fledged pre-clinical contract services provider. 
Here’s what we’ve been up to along the way!

15 November 2022
Magnitude Biosciences secures new investment to accelerate scaling of its specialist anti-ageing research services

Magnitude Biosciences Limited, a specialist provider of C. elegans research services to the longevity, nutraceuticals and pharmaceutical industries, has closed a fourth round of investment to accelerate the scaling of its business.

Read More
7 October 2022
Magnitude Biosciences Appoints New CEO Fozia Saleem to Drive Growth

North East UK Biotech Magnitude Biosciences announces new CEO, Fozia Saleem, to accelerate the growth of the world leading C. elegans CRO.

Read More
26 September 2022
C. elegans capabilities in the toxicology field

C. elegans is a proven model for toxicology research and has numerous advantages over other animal models

Read More
18 September 2022
SMER28 Extends Healthspan – Revealing a New Target for Ageing Therapeutics

Biotech entrepreneur Ethan Perlstein works with Magnitude Biosciences to reveal a new target for ageing therapeutics.

Read More
23 August 2022
AB Biotek works with Magnitude Biosciences to accelerate probiotics development

Magnitude Biosciences worked with the AB Biotek HNH scientific team to design and implement novel techniques for testing the health impact of probiotics. Download the case study for the full detail on how worms can be used to accelerate microbiome research.

Read More
24 March 2022
Ageing drug discovery biotech sees exciting early in vivo data for lead compound

Five Alarm Bio works with Magnitude Biosciences to develop therapeutics for age-related disease.

Read More
Magnitude Biosciences secures new investment to accelerate scaling of its specialist anti-ageing research services
Magnitude Biosciences Limited, a specialist provider of C. elegans research services to the longevit...Read More
CEO and CSO of Magnitude Biosciences
Magnitude Biosciences Appoints New CEO Fozia Saleem to Drive Growth
North East UK Biotech Magnitude Biosciences announces new CEO, Fozia Saleem, to accelerate the growt...Read More
C. elegans capabilities in the toxicology field
C. elegans is a proven model for toxicology research and has numerous advantages over other animal m...Read More
SMER28 Extends Healthspan – Revealing a New Target for Ageing Therapeutics
Biotech entrepreneur Ethan Perlstein works with Magnitude Biosciences to reveal a new target for age...Read More
Ageing drug discovery biotech sees exciting early in vivo data for lead compound
Five Alarm Bio works with Magnitude Biosciences to develop therapeutics for age-related disease. ...Read More
Magnitude Biosciences CEO David Weinkove appointed new Chair of British Society for Research on Ageing
The British Society for the Research on Ageing (BSRA) announces its new Chair, biology of ageing res...Read More
Frontiers in Aging: Applying C. elegans to industrial drug discovery
Just published in Frontiers in Aging: Applying C. elegans to industrial drug discovery...Read More
Magnitude Biosciences, Perfectus Biomed Group and University of Kent Project Funded by National Biofilms Innovation Centre for Tackling and Exploiting Biofilms
The joint project for Magnitude Biosciences, Perfectus Biomed Group and the University of Kent aims ...Read More
Research on ageing leader Magnitude Biosciences expands its project delivery team to meet increased demand
Hannah Raddings (right) and Alana Mullins (centre) with Magnitude Biosciences Head of Experiments Mi...Read More
Could C. elegans be the key to slowing ageing?
Originally published in Health Tech World: https://www.htworld.co.uk/interviews/could-c-elegans-be-t...Read More
Frontiers in Longevity: How do we slow human ageing?
How do we slow the process of Ageing? David Weinkove discusses learnings from the Clubhouse event "T...Read More
Translating groundbreaking drug development ideas into therapies with worms: takeaways from the joint ELRIG and British Pharmacological Society 2021 meeting
Some fascinating ideas came out of the Translating Ideas Into Therapies meeting held June 30-July 1 ...Read More
Unlocking the microbiome as a target for drug discovery using C. elegans
The human microbiome holds great promise for modern medicine but is still largely a mystery to scie...Read More
Magnitude Biosciences recognised in Developed in Durham as local success story
Magnitude Biosciences has been recognised by Developed in Durham....Read More
Magnitude Biosciences to attend Translating Ideas Into Therapies 2021 and the International C. elegans Conference in June 2021
June 2021 marks an exciting month as we see some of our C. elegans thought leaders speaking at key e...Read More
Holly and Maggie
A child, a worm, and a new era of drug discovery
This article will tell the story of how C. elegans enabled a life-changing effects drug therapy for ...Read More
The Magnitude Biosciences team
Magnitude Biosciences launches new website
Magnitude Biosciences, the world’s leading C. elegans Contract Research Organisation (CRO) and com...Read More
Magnitude Biosciences secures its second round of funding to support its pre-clinical research services
Biosciences spinout secures six-figure funding to create new North East jobs A spinout enterprise fr...Read More
Magnitude Biosciences will be pleased to attend Vermidi 23 online, co-ordinated from the Sorbonne, Paris.
Magnitude Biosciences will be pleased to attend Vermidi 23 online, co-ordinated from the Sorbonne, P...Read More
Magnitude Biosciences announces new hires to support continued growth
Durham, UK - March 2021 Magnitude Biosciences, a spin-out from Durham University and the leading con...Read More
Magnitude Biosciences secures UK government Future Fund to expand its workforce.
Durham, UK - August 2020 Research into new medicines is needed more than ever, but research labs acr...Read More
Magnitude Biosciences' new COVID-19 compatible laboratory is fully operational and we are ready to support your research
Magnitude Biosciences moves its unique COVID-19 compatibletechnology to a new lab at NETPark in Sedg...Read More
Magnitude Biosciences will be presenting at the online European Worm Meeting.
Magnitude Biosciences will be presenting at the online European Worm Meeting....Read More
Magnitude Biosciences now offers Transgenic Services after acquiring Invermis Ltd.
Magnitude Biosciences now offers Transgenic Services after acquiring Invermis Ltd. ...Read More
The Magnitude Biosciences team
Magnitude Biosciences enters the world of Contract Research Services, as a spin-out from Durham University, UK
Magnitude Biosciences enters the world of Contract Research Services, as a spin-out from Durham Univ...Read More
Magnitude Biosciences secures new investment to accelerate scaling of its specialist anti-ageing research services
Magnitude Biosciences Limited, a specialist provider of C. elegans research services to the longevit...Read More
CEO and CSO of Magnitude Biosciences
Magnitude Biosciences Appoints New CEO Fozia Saleem to Drive Growth
North East UK Biotech Magnitude Biosciences announces new CEO, Fozia Saleem, to accelerate the growt...Read More
C. elegans capabilities in the toxicology field
C. elegans is a proven model for toxicology research and has numerous advantages over other animal m...Read More
SMER28 Extends Healthspan – Revealing a New Target for Ageing Therapeutics
Biotech entrepreneur Ethan Perlstein works with Magnitude Biosciences to reveal a new target for age...Read More
AB Biotek works with Magnitude Biosciences to accelerate probiotics development
Magnitude Biosciences worked with the AB Biotek HNH scientific team to design and implement novel te...Read More
Ageing drug discovery biotech sees exciting early in vivo data for lead compound
Five Alarm Bio works with Magnitude Biosciences to develop therapeutics for age-related disease. ...Read More
Case Study: Measuring efficacy to slow ageing for drug discovery biotech Five Alarm Bio
Five Alarm Bio, a UK drug discovery startup focussing on the underlying mechanisms of ageing to deve...Read More
Tiny Worms- Experiments Fast
David Weinkove, CEO of Magnitude Biosciences joins New Matter ...Read More
Magnitude Biosciences CEO David Weinkove appointed new Chair of British Society for Research on Ageing
The British Society for the Research on Ageing (BSRA) announces its new Chair, biology of ageing res...Read More
Case Study: Michelin & Magnitude Biosciences
Michelin, a Fortune 500 consumer good manufacturing company and the global leader in tyre manufactur...Read More
ELRIG Drug Discovery 2021
Take a look at our Poster from ELRIG Drug Discovery 2021: Automated Monitoring of C. elegans&nb...Read More
Fat Staining Assay Datasheet
Determine whether caloric restriction could be involved in your test compound's mode of action. ...Read More
Frontiers in Aging: Applying C. elegans to industrial drug discovery
Just published in Frontiers in Aging: Applying C. elegans to industrial drug discovery...Read More
Magnitude Biosciences, Perfectus Biomed Group and University of Kent Project Funded by National Biofilms Innovation Centre for Tackling and Exploiting Biofilms
The joint project for Magnitude Biosciences, Perfectus Biomed Group and the University of Kent aims ...Read More
Research on ageing leader Magnitude Biosciences expands its project delivery team to meet increased demand
Hannah Raddings (right) and Alana Mullins (centre) with Magnitude Biosciences Head of Experiments Mi...Read More
Could C. elegans be the key to slowing ageing?
Originally published in Health Tech World: https://www.htworld.co.uk/interviews/could-c-elegans-be-t...Read More
Frontiers in Longevity: How do we slow human ageing?
How do we slow the process of Ageing? David Weinkove discusses learnings from the Clubhouse event "T...Read More
C. elegans to accelerate industrial drug discovery and address the costs and challenges of early preclinical research
Magnitude Bioscience CEO, David Weinkove, discusses the application of C. elegans to accelerate the ...Read More
Translating groundbreaking drug development ideas into therapies with worms: takeaways from the joint ELRIG and British Pharmacological Society 2021 meeting
Some fascinating ideas came out of the Translating Ideas Into Therapies meeting held June 30-July 1 ...Read More
Unlocking the microbiome as a target for drug discovery using C. elegans
The human microbiome holds great promise for modern medicine but is still largely a mystery to scie...Read More
Developing a System to Quantify Efficacy of Neurodegeneration Therapeutics Using Automated Monitoring of C. elegans
Check out our poster showing how we can quantify the efficacy of neurodegeneration models...Read More
C. elegans mobility decline
This video shows an automated method to quantify that decline developed by Magnitude Biosciences whi...Read More
Neuronal SKN-1B modulates nutritional signalling pathways and mitochondrial networks to control satiety
Neuronal SKN-1B modulates nutritional signalling pathways and mitochondrial networks to control sati...Read More
Chemosensory Neurons Modulate the Response to Oomycete Recognition in Caenorhabditis elegans
The Barkoulas Lab, including our own Michael Fasseas , find an Oomycetes recognition response in C....Read More
UK SPINE Recording
Our CEO, David Weinkove, discusses the use of C. elegans and how they could be used in the...Read More
Microbiome SIG Webinar Series
Our CEO, Dr. David Weinkove, explains how healthspan readouts can be used to understand mechanisms i...Read More
Automated Imaging of C. elegans for Ageing, Neurodegeneration and Behaviour
How large scale non-invasive imaging of C. elegans to enable reliable measurement of Agein...Read More
C. elegans Automated Imaging Platform
Magnitude Biosciences presentation from ELRIG online 2020 on the use of C. elegans in pre-...Read More
C. elegans Automated Imaging in Drug Discovery
De-risking drug candidates ahead of rodent studies with a non-mammalian model for ageing, neurodegen...Read More
An overview of the use of C. elegans in longevity research including the genetic manipulation of animals.
An overview of the use of C. elegans in longevity research including the genetic manipulat...Read More
Magnitude Biosciences recognised in Developed in Durham as local success story
Magnitude Biosciences has been recognised by Developed in Durham....Read More
Magnitude Biosciences to attend Translating Ideas Into Therapies 2021 and the International C. elegans Conference in June 2021
June 2021 marks an exciting month as we see some of our C. elegans thought leaders speaking at key e...Read More
Holly and Maggie
A child, a worm, and a new era of drug discovery
This article will tell the story of how C. elegans enabled a life-changing effects drug therapy for ...Read More
The Magnitude Biosciences team
Magnitude Biosciences launches new website
Magnitude Biosciences, the world’s leading C. elegans Contract Research Organisation (CRO) and com...Read More
Magnitude Biosciences secures its second round of funding to support its pre-clinical research services
Biosciences spinout secures six-figure funding to create new North East jobs A spinout enterprise fr...Read More
Magnitude Biosciences will be pleased to attend Vermidi 23 online, co-ordinated from the Sorbonne, Paris.
Magnitude Biosciences will be pleased to attend Vermidi 23 online, co-ordinated from the Sorbonne, P...Read More
Magnitude Biosciences announces new hires to support continued growth
Durham, UK - March 2021 Magnitude Biosciences, a spin-out from Durham University and the leading con...Read More
Magnitude Biosciences secures UK government Future Fund to expand its workforce.
Durham, UK - August 2020 Research into new medicines is needed more than ever, but research labs acr...Read More
Magnitude Biosciences' new COVID-19 compatible laboratory is fully operational and we are ready to support your research
Magnitude Biosciences moves its unique COVID-19 compatibletechnology to a new lab at NETPark in Sedg...Read More
Magnitude Biosciences will be presenting at the online European Worm Meeting.
Magnitude Biosciences will be presenting at the online European Worm Meeting....Read More
Magnitude Biosciences now offers Transgenic Services after acquiring Invermis Ltd.
Magnitude Biosciences now offers Transgenic Services after acquiring Invermis Ltd. ...Read More
The Magnitude Biosciences team
Magnitude Biosciences enters the world of Contract Research Services, as a spin-out from Durham University, UK
Magnitude Biosciences enters the world of Contract Research Services, as a spin-out from Durham Univ...Read More

CONTACT US

Get in touch today to find out how we can 
support you to accelerate your research

CONTACT US

Get in touch today to find out how we can 
support you to accelerate your research
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram